Endo International Plc (ENDPQ) Return on Equity ROE from the fourth quarter 2023 to fourth quarter 2022 and annually, average high and low, overall ranking from Dec 31 2023 to Dec 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Endo International Plc  (ENDPQ)

Endo International Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Endo International Plc in the fourth quarter 2023?
Due to the lack of equity, it was not possible to calculate Endo International Plc's return on equity (ROE) in its fourth quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -2,450 -252 -946 -2,854 -2,923
Return On Equity (TTM) - - - - -
ENDPQ's Total Ranking # # # # #
Equity (TTM) in Millions -6,598 -4,159 -4,127 -4,154 -4,162
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to ENDPQ Management Effectiveness >> ENDPQ's 5 Years Annual ROE >> Compare ENDPQ ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





ENDPQ Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Equity in Millions -6,598 -4,162 -1,244 -648 -867
Y / Y Equity Change - - - - -
Net Income in Millions -2,450 -2,923 -613 184 -423
Y / Y Net Income Change - - - - -
Return On Equity - - - - -

Back to ENDPQ Management Effectiveness >> ENDPQ's 5 Years Annual ROE >> Compare ENDPQ ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ENDPQ's' Return on Equity at Yahoo Finance
ENDPQ's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ENDPQ's Competitors
Subscribers only: Roe for Endo International Plc's Suppliers
Subscribers only: Return On Equity for ENDPQ's Customers




Companies with similar Return On Equity at Dec 31 2023, within Healthcare Sector ROE
Biomx Inc  140.47 %
Icecure Medical Ltd  120.46 %
Scynexis Inc   117.56 %
Viskase Holdings inc   114.23 %
Amgen Inc   103.27 %
Entera Bio Ltd   101.78 %
Profound Medical Corp   91.63 %
Waters Corporation  87.01 %
Dariohealth Corp   85.94 %
Cv Sciences Inc   80.98 %
Davita Inc   78.94 %
Novo Nordisk A  76.82 %
Galmed Pharmaceuticals Ltd   74.21 %
Idexx Laboratories Inc  71.66 %
Medpace Holdings Inc   63.98 %
Voyager Therapeutics Inc   63.89 %
Puma Biotechnology Inc   58.19 %
Enzo Biochem Inc  53.73 %
Lantheus Holdings Inc   52.00 %
Johnson and Johnson  48.95 %
Zoetis Inc   48.81 %
Nrc Health  47.79 %
Eli Lilly And Company  46.98 %
Elite Pharmaceuticals Inc   46.73 %
Tenet Healthcare Corp  46.41 %
Siga Technologies Inc  44.84 %
Star Equity Holdings Inc   42.21 %
Gsk Plc  40.50 %
Abbvie Inc   40.00 %
Lite Strategy Inc   39.72 %

Date modified: 2026-09-08T15:11:11+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.